Clinical Trial: Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502378) titled 'Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency' on March 25.

Brief Summary: STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.

Study Start Date: March 27

Study Type: INTERVENTIONAL

Condition: Ocular Surface Disease Neurotrophic Keratopathy Stage 1

Intervention: DRUG: Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period.

This is an FDA approved drug. The participants will be educated on the...